Ursodeoxycholic acid concept stocks strengthen! Sinotherapeutical's "one" word is up and down, and many stocks such as Common Pharmaceutical have soared

【Pharmaceutical Network Pharmaceutical Stock Market】 In early trading on December 7, beardeoxycholic acid concept stocks strengthened in early trading, and the science and technology innovation board Xuantai Pharmaceutical's "one" character rose to the limit, in addition, beardeoxycholic acid concept stocks Zhonggong Pharmaceutical, Guangshengtang, Shanghai Kaibao, Fu'an Pharmaceutical, etc
.
have soared 。 On the news, on December 5, 2022, researchers at the University of Cambridge in the United Kingdom published a research paper titled "FXR inhibition may protect from SARS-CoV-2infection by reducing ACE2" in the journal Nature, which showed that ursodeoxycholic acid (UDCA), a drug for treating liver disease, can shut down ACE2 receptors, closing the door for the virus to enter cells
。 According to the intraday news on December 7, Xuantai Pharmaceutical touched the limit at 9:25
.
The current price is 13.
86, up 20.
0%.

Its industry, chemical pharmaceuticals, is currently rising
.
The stock is a hot stock
of state-owned enterprise reform, innovative drugs, and Shanghai state-owned enterprise reform concept.
Recently, Sinotherapeutics said when undergoing adjustment research that the company's ursodeoxycholic acid capsule products will be commercially supplied
in the near future.
According to the data, the main business of Sinotherapeutics includes the research and development, production and sales of high-end preparations, and the preparation CRO/CMO business
.
The company's preparation CRO/CMO business relies on the company's insoluble drug solubilization technology platform, sustained and controlled-release drug preparation research and development platform, and Sino-US compliant production and quality management system; The main customer groups are domestic and foreign innovative drug enterprises
.
At present, among the customer projects of the company providing formulation CRO services, a number of new drugs have been approved for marketing by the National Medical Products Administration of China, and follow-up CMO services are provided by its subsidiary Jiangsu Xuantai Pharmaceutical Co.
, Ltd.
, including orebatinib tablets, omacycline tosylate tablets and newly approved Linplisset tablets
.
According to the third quarter report of Sinotherapeutics in 2022, the company's main revenue in the first three quarters of this year was 187 million yuan, a year-on-year decrease of 19.
15%; the net profit attributable to the parent was 67.
1026 million yuan, an increase of 10.
02% over the same period last year; Non-net profit was 65.
635 million yuan, up 6.
3%
from the same period last year.
On December 7, Common Pharmaceutical opened up 5%, as of 9:26, it was 28.
01 yuan, with a transaction of 15.
5203 million yuan and a turnover rate of 0.
94%.

According to the data, Gong Gong Pharmaceutical is an enterprise specializing in the research and development, production and sales of steroid hormone drug raw materials, and its main products are starting materials and intermediates
required for the production of steroid drugs 。 According to the 2022 third quarter report of Mutual Pharmaceutical, the company's main revenue in the first three quarters of this year was 447 million yuan, an increase of 0.
2% year-on-year; the net profit attributable to the parent was 39.
9175 million yuan, down 26.
17% from the same period last year; deducted non-net profit of 36.
3121 million yuan, down 18.
17% from the same period last year; On December 7, Guangshengtang opened up 5%, as of 9:26, it was 39.
99 yuan, with a transaction of 15.
948 million yuan, and a turnover rate of 0.
30%.

According to the data, Guangshengtang is committed to creating innovative drugs that belong to the Chinese in China's fight against viruses, hepatitis B, liver cancer and liver fibrosis, and contributing core strength
to the innovation and development of China's independent and controllable drug research and development.
Data show that in the first three quarters of 2022, the company's operating income was 297,466,452.
67 yuan, an increase of 9.
74% over the same period of the previous year; The company's research and development expenses were 120,149,542.
08 yuan, an increase of 169.
27%
over the same period of the previous year.
On December 7, Shanghai Kaibao opened up 5%, as of 9:26, it was 7.
13 yuan, with a transaction of 20.
0178 million yuan, and a turnover rate of 0.
31%.

According to the data, Shanghai Kaibao's main product sputum heat clear injection main effect is to clear heat, detoxify, phlegm, mainly used for the treatment of acute and chronic bronchitis, pneumonia and upper respiratory tract infections caused by bacteria or viruses, symptoms include fever, cough, sputum production, etc
.
On December 7, Fu'an Pharmaceutical rose 5% intraday, as of 9:39, it was quoted at 4.
01 yuan, with a transaction of 55.
85 million yuan and a turnover rate of 1.
49%.

According to the data, Fu'an Pharmaceutical was established on February 25, 2004, and its main business is engaged in the research and development, production and sales
of chemical drugs.
Data show that in the first three quarters of 2022, Fu'an Pharmaceutical's revenue was about 1.
784 billion yuan, and the net profit attributable to shareholders of listed companies was about 136 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.